Rebecca Whelan

Rebecca Whelan

New Methods for Detection and Treatment of Ovarian Cancer

Biography

2018-present
Associate Professor, University of Notre Dame
2014-2018
Chair of Chemistry and Biochemistry, Oberlin College
2011-2018
Associate Professor, Oberlin College
2005-2011
Assistant Professor, Oberlin College
2003-2004
Postdoctoral Researcher, University of Michigan
2003
Ph.D. in Chemistry, Stanford University
1996
B.A. in Chemistry and English, Lawrence University

Selected Awards

2011
Henry Dreyfus Teacher-Scholar Award
2010
Distinguished Alumni Scholar, Stanford University
2008
Chair's Award, Gordon Research Conference in Bioanalytical Sensors
2008
W.M. Keck Foundation Fellowship

Research Interests

Research in the Whelan lab is motivated by the need to detect and treat ovarian cancer in its early stages, when therapeutic intervention is most effective. We approach the problem of ovarian cancer detection with a diverse tool kit drawn from bioanalytical chemistry, molecular biology, bioinformatics, and nanoscience. We have an abiding interest in fundamental analytical method development as well as biomedical and clinical application. Ongoing projects include:

Identifying and Validating DNA Aptamers for Ovarian Cancer Biomarkers

Aptamers are single stranded oligonucleotides - DNA or RNA - that are selected out of a large, random pool on the basis of a particular function. Often aptamers function as high-affinity binders to biological molecules. The process of selecting aptamers ("SELEX") relies on repeated cycles of selection and amplification until a small number of oligonucleotides with the desired binding property dominate the pool. We are currently selecting aptamers for the important ovarian cancer biomarkers MUC16 (CA125), HE4, and mesothelin. Informed by the particular attributes of the protein target, we tailor the aptamer selection process to fit. Selection modes we have recently employed include capillary electrophoresis-based (CE-SELEX), One- Pot SELEX, cell SELEX, and magnetic-bead-based fluidic SELEX. Every selection process concludes with high-throughput sequencing of the evolved oligonucleotide pool, followed by bioinformatics to mine the resulting sequence data for the best aptamers. Bioinformatics also identifies bias, contamination, and the development of structural trends over the selection process. The binding properties of aptamer candidates are evaluated using capillary electrophoresis, fluorescence anisotropy, surface plasmon resonance spectroscopy, isothermal titration calorimetry, and competitive ELISA immunoassay. The resulting aptamers can be used as substitutes for antibodies in any application for which affinity recognition is valuable.

Proteomics Analysis of Ovarian Cancer Biomarkers

CA125 is the most widely used biomarker for clinical monitoring of epithelial ovarian cancer. Serum levels of CA125 are monitored during treatment, and increases correlate with cancer recurrence. CA125 is the repeating peptide epitope of the mucin protein MUC16 and is currently detected via double determinant immunoassay. Previous work from our lab and others indicates that the antibodies used in existing CA125 clinical assays do not respond uniformly to all domains of CA125, suggesting that these assays underestimate levels of this biomarker in patients, and that earlier detection would be enabled by new assays based on improved affinity recognition. Importantly, the epitopes that are recognized by the antibodies used in the clinic are not known. In collaboration with the lab of Dr. Manish Patankar at the University of Wisconsin School of Medicine and Public Health, we are using capillary-electrophoresis-mass spectrometry (CE-MS) to characterize MUC16 (CA125) from various sources, including bacterial expression systems, mammalian cell lines, and ascites fluid from ovarian cancer patients. We will correlate amino acid sequence information with immunogenicity to the antibodies used in clinical assays. This study will enable us in future work to the test the hypothesis that heterogeneity in this protein has clinically relevant predictive power.

Recent Papers

  • Alharbi, Y.; Patankar, M. S.; Whelan, R. J. "Antibody based therapy for ovarian cancer." Ovarian Cancer Immunotherapy 2018, Farghaly, S., Ed. ISBN 9780190248208.
  • Garvin, M.C., Austin, A.L., Stracker, N.H., Slowinski, S.P., Rutter, J.E., Butler, M., Michel, M., Whelan, R.J. "Attraction of Culex pipiens to uropygial gland secretions does not explain feeding preference for American robins" 2018 Journal of Vector Ecology, 43 (1), pp. 110-116. DOI: 10.1111/jvec.12290
  • Scoville, D.J., Uhm, T.K.B., Shallcross, J.A., Whelan, R.J. "Selection of DNA Aptamers for Ovarian Cancer Biomarker CA125 Using One-Pot SELEX and High-Throughput Sequencing" 2017 Journal of Nucleic Acids, 2017, 9879135. DOI: 10.1155/2017/9879135
  • Pires, T. A.; Narovec, C. M.; Whelan, R. J. "Effects of cationic proteins on gold nanoparticle/aptamer assays." ACS Omega 2017, 2, 8222-8226. 10.1021/acsomega.7b01336
  • Kapur, A., Felder, M., Fass, L., Kaur, J., Czarnecki, A., Rathi, K., Zeng, S., Osowski, K.K., Howell, C., Xiong, M.P., Whelan, R.J., Patankar, M.S. "Modulation of oxidative stress and subsequent induction of apoptosis and endoplasmic reticulum stress allows citral to decrease cancer cell proliferation" 2016 Scientific Reports, 6, 27530. DOI: 10.1038/srep27530
  • Eaton, R.M., Shallcross, J.A., Mael, L.E., Mears, K.S., Minkoff, L., Scoville, D.J., Whelan, R.J. "Selection of DNA aptamers for ovarian cancer biomarker HE4 using CE-SELEX and high-throughput sequencing" 2015 Analytical and Bioanalytical Chemistry, 407 (23), pp. 6965-6973. DOI: 10.1007/s00216-015-8665-7

Contact Information

  • Associate Professor
  • Office: 140D McCourtney Hall
  • Phone: 574-631-1853
  • Send an email

Primary Research Areas

Research Specialties